Results For "Cerevel-Therapeutics"

1 News Found

AbbVie completes acquisition of Cerevel Therapeutics

News | August 03, 2024

AbbVie completes acquisition of Cerevel Therapeutics

Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia

Latest Stories

Bristol Myers Squibb presents data across targeted protein degradation research at EHA 2025

AstraZeneca collaborates with CSPC Pharmaceuticals focused on AI-enabled research

Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews

India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant

India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant

Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India

Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India

Dr. R. Ananthanarayanan CEO, Sajjan India

Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries

Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries

Dr. Aman Desai Promoter and Whole Time Director, Aether Industries

Packaging